UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
☑ | Filed by the Registrant | ☐ | Filed by a Party other than the Registrant |
CHECK THE APPROPRIATE BOX: | ||
☐ | Preliminary Proxy Statement | |
☐ | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
☐ | Definitive Proxy Statement | |
☑ | Definitive Additional Materials | |
☐ | Soliciting Material Under Rule 14a-12 |
Gilead Sciences, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX): | |||
☑ | No fee required. | ||
☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | ||
1) Title of each class of securities to which transaction applies: | |||
2) Aggregate number of securities to which transaction applies: | |||
3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |||
4) Proposed maximum aggregate value of transaction: | |||
5) Total fee paid: | |||
☐ | Fee paid previously with preliminary materials: | ||
☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. | ||
1) Amount previously paid: | |||
2) Form, Schedule or Registration Statement No.: | |||
3) Filing Party: | |||
4) Date Filed: |
GILEAD SCIENCES, INC. ATTN: INVESTOR RELATIONS 333 LAKESIDE DRIVE FOSTER CITY, CA 94404 | Your Vote Counts! GILEAD SCIENCES, INC. 2021 Annual Meeting | |||
| ||||
D42713-P48614 | ||||
|
You invested in GILEAD SCIENCES, INC. and it’s time to vote!
This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 12, 2021, 10:00 a.m. Pacific Time, virtually at www.virtualshareholdermeeting.com/GILD2021.*
* Due to the ongoing health and safety concerns related to the COVID-19 pandemic, the Annual Meeting will be held virtually this year.
Get informed before you vote
You can view the Notice and Proxy Statement, Form 10-K and Supplement online by visiting www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by making a request prior to April 28, 2021. To submit a request for a paper or email copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.
For complete information and to vote, visit www.ProxyVote.com | ||||
Control # |
Smartphone users Point your camera here and | Vote Virtually at the Meeting* May 12, 2021 | |
Virtually at: www.virtualshareholdermeeting.com/GILD2021 | ||
* | Please check the proxy materials for additional information and special requirements regarding meeting attendance and participation. |
V1
Vote at www.ProxyVote.com |
THIS IS NOT A VOTABLE BALLOT
This is an overview of the proposals being presented at the
upcoming Annual Meeting. We encourage you to access and
review all of the important information contained in the proxy
materials before voting. Please follow the instructions on the
reverse side to obtain the proxy materials and to vote on these
important matters.
Board | |||
Voting Items | Recommends | ||
1. | To elect the nine director nominees named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. | ||
Nominees: | |||
1a. | Jacqueline K. Barton, Ph.D. | For | |
1b. | Jeffrey A. Bluestone, Ph.D. | For | |
1c. | Sandra J. Horning, M.D. | For | |
1d. | Kelly A. Kramer | For | |
1e. | Kevin E. Lofton | For | |
1f. | Harish Manwani | For | |
1g. | Daniel P. O’Day | For | |
1h. | Javier J. Rodriguez | For | |
1i. | Anthony Welters | For | |
2. | To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2021. | For | |
3. | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | For | |
4. | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director. | Against | |
Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. |
D42714-P48614